A placebo-controlled dose-finding study with bambuterol in elderly patients with asthma

Area of Science:

• Pharmacology
• Pulmonology
• Geriatrics

Background:

• Elderly asthma patients require effective and safe long-term bronchodilator therapy.
• Bambuterol hydrochloride is a long-acting prodrug of terbutaline, offering potential for once-daily dosing.

Purpose of the Study:

• To evaluate the efficacy and safety of bambuterol hydrochloride in elderly asthmatic patients.
• To determine the optimal once-daily dosage for this population.

Main Methods:

• Randomized, crossover, double-blind, placebo-controlled study.
• Inclusion of elderly asthmatic patients aged 64-82 years.
• Administration of placebo and bambuterol hydrochloride at 5 mg, 10 mg, and 20 mg once daily for one week per dose.

Main Results:

• Plasma terbutaline concentrations increased linearly with bambuterol hydrochloride dose (p < 0.001).
• Peak expiratory flow rate significantly improved with 10 mg and 20 mg doses compared to placebo (p < 0.001).
• Reduced need for supplemental beta 2-agonist therapy during the night for 10 mg and 20 mg doses (p < 0.05 and p < 0.01, respectively).
• Mild, dose-related side effects (tremor, palpitations) were observed; no significant effects on blood pressure or pulse.

Conclusions:

• Once-daily bambuterol hydrochloride at 10 mg or 20 mg is effective in improving pulmonary function in elderly asthma patients.
• The drug is well-tolerated in this population, suggesting it as a viable bronchodilator option.
• Further research may explore long-term safety and efficacy profiles.